Jace Yawnick was diagnosed with primary mediastinal B-cell non-Hodgkin lymphoma in Jan. 2024 at 25 years old. However, Yawnick's first onset of symptoms dates back to Aug. 2023, when he was ...

Cancer survivor Zoe Plastiras hopes her message provides some reassurance by highlighting advances in cancer treatment.

Dan Evans, 19, from Newark in Nottinghamshire, described his huge relief ringing the "cancer-free bell" at the teenage cancer ...

Three subtypes have been identified by gene-expression studies; germinal center (GC) DLBCL, non-GC DLBCL, and mediastinal large B-cell lymphoma. GC and non-GC DLBCL differ with respect to the cell ...

Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...

The direct antiglobulin test was positive for anti-C3d specificity, with cold agglutinin titer confirming the diagnosis of CAD.

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, hurdles that include availability and cost remain to its widespread ...

The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.

The treatment will be available in the third line setting for all adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...